Johnson & Johnson (JNJ) Is Becoming a Growth Stock. Does AbbVie (ABBV) Make JNJ Look Expensive?
Johnson & Johnson (JNJ) Is Becoming a Growth Stock. Does AbbVie (ABBV) Make JNJ Look Expensive? Insider Monkey
Covered in this story
What has happened since
- Johnson & Johnson is up 0.3% since this was published.
- AbbVie is up 1.7% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Johnson & Johnson
- RBC Capital Markets: $255 → $290 by Oct 2027 · Outperform via Investing.com
- Bank of America: $265 → $278 by Sep 2027 · Neutral via AOL.com
- UBS: $275 → $320 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $JNJ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Johnson & Johnson →Dalsna Finance is currently tracking 44 stories mentioning Johnson & Johnson, the earliest published 14 Aug 2026.
Summary aggregated from Insider Monkey's public RSS feed. The full reporting belongs to Insider Monkey — please read it on their site.